Virginia Kaklamani, MD, DSc
Virginia Kaklamani, MD, DSc, is a professor of medicine in the division of hematology/oncology at the University of Texas Health Sciences Center in San Antonio and is the leader of the breast cancer program at the Mays Cancer Center, home to University of Texas Health San Antonio MD Anderson.
Dr. Kaklamani was head of the translational breast cancer program at Northwestern University and co-director of the cancer genetics program at the same institution. She has also served as the associate director for clinical research at University of Texas Health San Antonio.
Her research interests include designing clinical trials with targeted agents. Dr. Kaklamani has also identified several genetic mutations that link obesity and breast cancer.
I still love working in the clinic, helping my patients and trying to solve their particular issues. During my residency, I cared for a large and diverse population of cancer patients, which was a fulfilling experience. And I never looked back on my decision to become an oncologist.
– Dr. Virginia Kaklamani, MD, The ASCO Post
- Medical Oncology, Hematology, Internal Medicine
- Northwestern University - Evanston, IL
- Master of Science, Clinical Investigation
- University of Athens, School of Health Sciences - Athens, GR
- Doctor of Medicine
- University of Texas Health Sciences Center - San Antonio, TX
- Professor of Medicine, Division of Hematology and Medical Oncology
- UT Health San Antonio MD Anderson Cancer Center
- Breast Cancer Program Leader
Awards and distinctions
Professional memberships and board positions
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM.
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group.
In the media
- San Antonio Breast Cancer Symposium 2017
- Doctoring is a Family Tradition for Medical Oncologist Virginia Kaklamani, MD - The ASCO Post
Connect on social media
- Follow Dr. Kaklamani on Twitter